Back To Search Instructions
Protocols
8 protocols meet the specified criteria
Disease Site: Breast - Male
Protocol No.TitleStatus
1300000027S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapyOpen
1300000710A single arm Phase II trial to assess association of BRCA1 protein expression with overall response rate in patients with metastatic breast cancer on pegylated liposomal doxorubicinOpen
1312169608Phase II Trial of Metronomic Eribulin (Halaven) In Pretreated Metastatic Breast Cancer (MBC)Open
1408438520A011202 A Randomized Phase III Trial Evaluating The Role Of Axillary Lymph Node Dissection In Breast Cancer Patients (Ct1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant ChemotherapyOpen
1507019170EA1131 A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant ChemotherapyOpen
1511200024An Open-Label, Single-Arm, Phase II Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy In Patients With Her2-Positive Metastatic Breast Cancer (Patricia)Open
1608779834A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 (PD-1), AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES, IN PATIENTS WITH ADVANCED MALIGNANCIESOpen
PHX-15-0013-10-15S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy Open